Stocks & Investing
Stocks and Investing
Stocks and Investing
Mon, December 17, 2012
[ Mon, Dec 17th 2012
] - WOPRAI
[ Mon, Dec 17th 2012
] - WOPRAI
[ Mon, Dec 17th 2012
] - WOPRAI
[ Mon, Dec 17th 2012
] - WOPRAI
[ Mon, Dec 17th 2012
] - WOPRAI
[ Mon, Dec 17th 2012
] - WOPRAI
[ Mon, Dec 17th 2012
] - WOPRAI
[ Mon, Dec 17th 2012
] - Market Wire
[ Mon, Dec 17th 2012
] - WOPRAI
[ Mon, Dec 17th 2012
] - WOPRAI
[ Mon, Dec 17th 2012
] - Market Wire
[ Mon, Dec 17th 2012
] - Market Wire
[ Mon, Dec 17th 2012
] - Market Wire
[ Mon, Dec 17th 2012
] - WOPRAI
[ Mon, Dec 17th 2012
] - WOPRAI
[ Mon, Dec 17th 2012
] - WOPRAI
[ Mon, Dec 17th 2012
] - WOPRAI
[ Mon, Dec 17th 2012
] - WOPRAI
[ Mon, Dec 17th 2012
] - WOPRAI
[ Mon, Dec 17th 2012
] - WOPRAI
[ Mon, Dec 17th 2012
] - WOPRAI
[ Mon, Dec 17th 2012
] - WOPRAI
Sumant Kulkarni Initiated (BIIB) at Hold and Held Target at $144 on, Dec 17th, 2012
Sumant Kulkarni of Canaccord Genuity, Initiated "Biogen Inc." (BIIB) at Hold and Held Target at $144 on, Dec 17th, 2012.
Sumant has made no other calls on BIIB in the last 4 months.
There are 4 other peers that have a rating on BIIB. Out of the 4 peers that are also analyzing BIIB, 1 agrees with Sumant's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Jay Olson of "Oppenheimer" Downgraded from Buy to Hold on, Thursday, October 4th, 2012
These are the ratings of the 3 analyists that currently disagree with Sumant
- Christopher Raymond of "Piper Sandler" Maintained at Buy with Increased Target to $179 on, Thursday, October 18th, 2012
- Evan Seigerman of "Credit Suisse" Maintained at Buy with Increased Target to $175 on, Monday, October 8th, 2012
- Andrew Peters of "Deutsche Bank" Maintained at Strong Buy with Increased Target to $160 on, Thursday, September 6th, 2012
